A month has gone by since the last earnings report for Revolution Medicines, Inc. (RVMD). Shares have added about 6.6% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is Revolution Medicines due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.

Q2 Loss Wider Than Expected, Sales Nil

Revolution Medicines reported an adjusted loss of $2.34 per share in the second quarter of 2026, wider than the Zacks Consensus Estimate of a loss of $1.93.

The adjusted figure excluded a non-cash charge of $151 million tied to a change in the fair value of warrants assumed through the EQRx acquisition, which closed in 2023. Including this item, the reported loss was $3.06 per share. The company had incurred a loss of $1.31 per share in the year-ago quarter.

Currently, the company does not have any approved product in its portfolio. It generated no revenues in the quarter.

Operating Expenses See a Significant Increase

Research and development expenses surged 76% year over year to around $395 million. The increase reflected higher costs associated with clinical studies and manufacturing for the company's pipeline candidates, along with increased employee-related expenses.

General and administrative expenses increased nearly 172% to more than $110 million. The increase was caused by higher personnel and stock-based compensation costs, increased commercial preparation activities and elevated administrative expenses.

2026 Expense Outlook Moves Higher Again

The company revised its operating expenses guidance for the second time this year. It expects the figure to be between $2.1 billion and $2.2 billion, up from the previous projection of $1.7 billion to $1.8 billion.

The updated forecast includes expected non-cash stock-based compensation expenses of $270 million to $290 million compared with the prior estimate of $260 million to $280 million.

Management intends to increase spending on commercial and clinical manufacturing, expand the company's development programs and strengthen launch readiness in the United States and international markets.

Improved Cash Position

The company ended June with cash, cash equivalents and marketable securities of $3.9 billion, up from $1.9 billion as of March 31, 2026.

The increase was primarily driven by $2.225 billion in gross proceeds from concurrent offerings of common stock and convertible senior notes completed in April 2026. The quarter-end balance also included a $250 million payment received from Royalty Pharma in May.